schistosomiasis / mycetoma

Development of pediatric formulation for schistosomiasis	Astellas engages in the development of a pediatric formulation of praziquantel for the treatment of Schistosomiasis in a consortium with Merck KGaA, Lygature, Swiss Tropical and Public Health Institute (Swiss TPH), Farmanguinhos, Schistosomiasis Control Initiative (SCI), Kenya Medical Research Institute (KEMRI), and Université Félix Houphouët-Boigny (UFHB). Astellas developed the pediatric formulation by using its own drug formulation technology and transferred it to Farmanguinhos and Merck KGaA. After successful completion of the Phase II clinical study, the consortium program is currently running the pivotal Phase III clinical trials in Kenya and Ivory Coast to gain data for registration and facilitate access to a novel orally dispersible tablet formulation for young children (below six years of age). Astellas is committed to providing the consortium with all necessary technical expertise. As a member of the consortium, Astellas is working with the partners aiming to have the product available for launch in the first endemic country in Africa in a few years.
Development of medicine for treating eumycetome	Eisai and the Drugs for Neglected Diseases initiative are conducting a clinical trial of E1224 (fosravuconazole), Eisai's anti-fungal drug for the treatment of eumycetoma, a fungal form of mycetoma in collaboration with the Mycetoma Research Center (MRC) of the University of Khartoum, Sudan. Mycetoma is one of the world's most neglected diseases, which was designated as a new NTD and added to WHO's list of NTDs in 2016.

Development of pediatric formulation for schistosomiasis

Astellas engages in the development of a pediatric formulation of praziquantel for the treatment of Schistosomiasis in a consortium with Merck KGaA, Lygature, Swiss Tropical and Public Health Institute (Swiss TPH), Farmanguinhos, Schistosomiasis Control Initiative (SCI), Kenya Medical Research Institute (KEMRI), and Université Félix Houphouët-Boigny (UFHB). Astellas developed the pediatric formulation by using its own drug formulation technology and transferred it to Farmanguinhos and Merck KGaA.

After successful completion of the Phase II clinical study, the consortium program is currently running the pivotal Phase III clinical trials in Kenya and Ivory Coast to gain data for registration and facilitate access to a novel orally dispersible tablet formulation for young children (below six years of age). Astellas is committed to providing the consortium with all necessary technical expertise. As a member of the consortium, Astellas is working with the partners aiming to have the product available for launch in the first endemic country in Africa in a few years.

Development of medicine for treating eumycetome

Eisai and the Drugs for Neglected Diseases initiative are conducting a clinical trial of E1224 (fosravuconazole), Eisai's anti-fungal drug for the treatment of eumycetoma, a fungal form of mycetoma in collaboration with the Mycetoma Research Center (MRC) of the University of Khartoum, Sudan. Mycetoma is one of the world's most neglected diseases, which was designated as a new NTD and added to WHO's list of NTDs in 2016.

TOP

schistosomiasis / mycetoma

schistosomiasis / mycetoma

Search